D&A at other companies
Other financials
Where this comes from
Reported directly by Axsome Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:AmortizationOfIntangibleAssets.
The official record: Axsome Therapeutics’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about Axsome Therapeutics's d&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Axsome Therapeutics's D&A?
- Axsome Therapeutics (AXSM) reported D&A of $1.57M in Q1 2026.
- How has Axsome Therapeutics's D&A changed year-over-year?
- Axsome Therapeutics's D&A decreased by 0.0% year-over-year, from $1.57M to $1.57M.
- What is the long-term trend for Axsome Therapeutics's D&A?
- Over 3 years (2022 to 2025), Axsome Therapeutics's D&A has grown at a 15.5% compound annual growth rate (CAGR), from $4.14M to $6.38M.
- What does D&A mean?
- The non-cash accounting expense for the gradual loss of value of assets over time.
- How do you interpret D&A?
- High levels indicate significant capital investment in infrastructure or acquired intangible assets.
- How does D&A compare across companies?
- Standard across all industries; analyzed to understand the underlying cash-generating capability of the business.